1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Species | Human |
| Cat.No | ABC-SC214Y |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
| Product Category | Stem Cells |
| Size/Quantity | 1 vial |
| Cell Type | Induced Pluripotent Stem Cell |
| Shipping Info | Dry Ice |
| Growth Conditions | 37℃, 5% CO2 |
| Source Organ | Human Skin Fibroblast |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human iPSCs |
HighQC™ Human iPSC Line (Episomal, Fibroblast) is a human induced pluripotent stem cell (iPSC) line generated using episomal-based reprogramming technology. This method involves the use of episomal vectors to introduce key reprogramming factors (such as OCT4, SOX2, KLF4, and c-MYC) into fibroblasts, inducing them to revert to a pluripotent state without integrating the vectors into the host genome. The resulting iPSCs exhibit typical pluripotent characteristics, including the expression of pluripotency markers like OCT4, SOX2, NANOG, and SSEA-4, and they are capable of forming embryoid bodies in culture. The Episomal vector remains in a non-integrated state within the cell and is naturally lost after reprogramming is complete, the adverse effects of long-term expression of reprogramming factors are reduced. HighQC™ Human iPSC Line (Episomal, Fibroblast) is suitable for a variety of applications, including disease modeling, drug discovery, and cell-based therapies.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
HighQC™ Human iPSC Line (Episomal, Fibroblast) is ideal for disease modeling, drug discovery, and regenerative medicine. Due to its non-integrating nature, it is widely used in gene therapy research and cell-based therapy development. Specific applications include studying genetic diseases such as cystic fibrosis and ALS, developing new antiviral drugs, or conducting regenerative research for liver and retinal diseases.